Literature DB >> 9243045

Antimicrobial dosing in obese patients.

R Wurtz1, G Itokazu, K Rodvold.   

Abstract

Although the dose of some drugs is commonly adjusted for weight, weight-related dosage adjustments are rarely made for most antimicrobials. We reviewed the English-language literature on antimicrobial pharmacokinetics and dosing in obesity. Although there are many potential pharmacokinetic consequences of obesity, the actual effect on the pharmacokinetics and clinical efficacy of most antimicrobials is unknown. Since approximately 30% of adipose is water, an empirical approach is use of the Devine formula to calculate ideal body weight (IBW), to which is added a dosing weight correction factor (DWCF) of 0.3 times the difference between actual body weight (ABW) and IBW (IBW + 0.3 x [ABW-IBW]) to arrive at a weight on which to base dosage of hydrophilic antibiotics. No studies confirm this approach for beta-lactam drugs. Clinical studies suggest a DWCF of approximately 0.40 for aminoglycosides and 0.45 for quinolones. Final dosage adjustments for antimicrobials with a narrow toxic-therapeutic window should be based on serum concentrations.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9243045     DOI: 10.1086/514505

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  29 in total

1.  Dosing ethambutol in obese patients.

Authors:  Jan-Willem Alffenaar; Tjip van der Werf
Journal:  Antimicrob Agents Chemother       Date:  2010-09       Impact factor: 5.191

2.  Population pharmacokinetics and pharmacodynamics of piperacillin in critically ill patients during the early phase of sepsis.

Authors:  Waroonrat Sukarnjanaset; Sutep Jaruratanasirikul; Thitima Wattanavijitkul
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-04-08       Impact factor: 2.745

3.  Pharmacokinetics and drug dosing in obese children.

Authors:  Jennifer G Kendrick; Roxane R Carr; Mary H H Ensom
Journal:  J Pediatr Pharmacol Ther       Date:  2010-04

4.  Dosing evaluation of continuous intravenous fentanyl infusions in overweight children: a pilot study.

Authors:  Emily C Gish; Donald Harrison; Andrew K Gormley; Peter N Johnson
Journal:  J Pediatr Pharmacol Ther       Date:  2011-01

5.  Obesity and Heart Failure as Predictors of Failure in Outpatient Skin and Soft Tissue Infections.

Authors:  Erin L Conway; John A Sellick; Kari Kurtzhalts; Kari A Mergenhagen
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

6.  Association between renal function and chemotherapy-related toxicity in older adults with cancer.

Authors:  Lindsay L Peterson; Arti Hurria; Tao Feng; Supriya G Mohile; Cynthia Owusu; Heidi D Klepin; Cary P Gross; Stuart M Lichtman; Ajeet Gajra; Ilya Glezerman; Vani Katheria; Laura Zavala; David D Smith; Can-Lan Sun; William P Tew
Journal:  J Geriatr Oncol       Date:  2016-11-14       Impact factor: 3.599

7.  Pharmacokinetics of ceftaroline in normal body weight and obese (classes I, II, and III) healthy adult subjects.

Authors:  Julie Ann Justo; Stockton M Mayer; Manjunath P Pai; Melinda M Soriano; Larry H Danziger; Richard M Novak; Keith A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  2015-04-20       Impact factor: 5.191

8.  Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults.

Authors:  M Chen; A N Nafziger; G L Drusano; L Ma; J S Bertino
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

9.  Diverticular disease and the obese patient.

Authors:  Eric K Johnson; Bradley J Champagne
Journal:  Clin Colon Rectal Surg       Date:  2011-12

Review 10.  Orthopedic trauma surgery in the morbidly obese patient.

Authors:  Anthony E Bozzio; Raj J Gala; Mario A Villasenor; Jiandon Hao; Cyril Mauffrey
Journal:  Eur J Orthop Surg Traumatol       Date:  2013-04-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.